Malaia L T, Lapshina L A, Bil'chenko A V, Shkapo V L
Lik Sprava. 1996 Jul-Sep(7-9):57-60.
Overall sixty patients with hypertensive disease were examined for clinical effectiveness of the prolonged-action inhibitor angiotensine-converting enzyme renitek (enalapril maleate, MJD). The treatment schedule included placebo over two weeks, renitek as monotherapy, 20 mg daily, over 6 weeks, if the patients failed to derive any benefit from the therapy, they were placed on a 4-week combined therapy of renitek plus hydrochlorothiazide. Renitek was found to dispel cardialgias, reduce frequency of attacks of cardiac angina. In the hemodynamic structure, a positive inotropic effect was identified as was reduction of energy expenditure of the myocardium, total peripheral vascular resistance, diminution of post- and preloads on the myocardium, with the mass of the left ventricular myocardium growing less.
总共对60例高血压病患者进行了长效血管紧张素转换酶抑制剂雷米普利（马来酸依那普利，MJD）的临床疗效检查。治疗方案包括为期两周的安慰剂治疗，之后雷米普利作为单一疗法，每日20毫克，持续6周，如果患者未从该疗法中获益，则给予为期4周的雷米普利加氢氯噻嗪联合治疗。结果发现雷米普利可消除心前区疼痛，减少心绞痛发作频率。在血流动力学结构方面，发现有正性肌力作用，同时心肌能量消耗、总外周血管阻力降低，心肌前后负荷减小，左心室心肌质量增长减缓。
